The first trials with tyrosine kinase inhibitors targeting EGFR in NSCLC were initiated in 2001, and, since that time, targeted therapies have emerged as an effective management strategy in lung cancer patients [14,15]. This evidence concerns the gene EGFR and lung carcinoma.